EU plans to shorten the regulatory data protection for new medicines will reduce investment in R&D and stifle innovation, Stefan Woxström, senior vice president of AstraZeneca Europe and Canada, has warned. “Of course, that will play a role when companies are looking into where they will put their future investments in new types of medicines,” he told Science|Business.